New cream offers hope for rare skin cancer patients
NCT ID NCT06698822
Summary
This study is testing whether a topical cream containing tofacitinib can safely and effectively treat early-stage cutaneous T-cell lymphoma, a rare type of skin cancer. The trial will enroll 20 adults whose cancer has returned or hasn't responded to at least one previous standard treatment. Participants will apply the cream to affected skin areas for 12 weeks, with options to continue treatment for up to a year while researchers monitor safety and skin improvement.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.